Indian pharma major Lupin Ltd has reported a 16% rise in consolidated profit after tax at £123 million in the first quarter ended June 30, riding on robust growth across its key markets.
The company had posted a consolidated Profit After Tax (PAT) at £106 million in the corresponding period last fiscal, Lupin Ltd said in a regulatory filing on Thursday (7).
Consolidated total revenue from operations in the first quarter was at £719.7 million as against £545 million in the year-ago period, it added.
Total expenses in the quarter under review rose at £555.6 million as compared to £428.9 million in the corresponding period last fiscal, the company said.
Commenting on the performance, Lupin Ltd Managing Director Nilesh Gupta said, "We are pleased to begin FY27 with a strong performance, driven by robust growth across our key markets and continued improvement in profitability."
The company's focus on execution, operational excellence, and sustained investments in technology and innovation continue to strengthen the business and position it for sustainable, profitable growth over the long term, he added.
In the first quarter, the US market posted sales of £298.7 million as against £209 million in the same period last fiscal, up 42.9%, while sales in India were up 13.9% at £206.9 million as compared to £181.7 million in the year-ago period, Lupin said.
Sales in other developed markets was at £99.4 million as against £67.4 million in the first quarter last fiscal, up 48.3%, it added.
